This medication is used to treat a certain type of cancer (multiple myeloma).It works by helping to slow the growth and spread of cancer cells.
Kyprolis (Carfilzomib) irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme that degrades unwanted cellular proteins. Inhibition of proteasome-mediated proteolysis results in a build-up of polyubiquinated proteins, which may cause cell cycle arrest, apoptosis, and inhibition of tumor growth.
Kyprolis (Carfilzomib) is injected into a vein through an IV. A healthcare provider will give you this injection.
Kyprolis (Carfilzomib) is given in a 28-day treatment cycle. You will receive an injection only on certain days of this cycle.
Your doctor will determine how many treatment cycles you should receive.
Dizziness, lightheadedness, nausea, vomiting, loss of appetite, diarrhea, constipation, and tiredness may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Store at room temperature away from moisture and heat.
Before taking Kyprolis (Carfilzomib), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before using this medication, tell your doctor or pharmacist your medical history, especially of: heart disease (such as heart failure, heart attack, heart rhythm problems), liver disease, certain viral infections (herpes, shingles).
Kyprolis is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.